PV Bulletin

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Swissmedic introduces a comprehensive checklist aimed at enhancing compliance with medical device vigilance standards in Swiss hospitals.

Primary source: Medical devices

PV Impact Brief

Urgency: HighConfidence: high

What changed

The introduction of a formal checklist tool for hospital inspections regarding materiovigilance, enhancing standards for incident reporting and vigilance roles.

Why it matters

The checklist establishes a framework for hospitals and associated stakeholders to ensure vigilance compliance, thus improving patient safety and regulatory adherence in the handling of medical devices.

Action needed

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Relevant for
Regulatory Intelligence LeadPV Quality Lead
Processes impacted
Inspection Readiness
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Checklist
Policy status
effective
Publication date
2026-07-17
Policy change
Swissmedic has published a new checklist for the inspection of materiovigilance (medical device vigilance) systems in hospitals. The tool is intended to help hospital facilities perform gap analyses and ensure compliance with GPMV-Spital requirements.

Key changes

Introduction of a formal checklist tool for hospital materiovigilance inspections, focusing on the reporting of incidents and the role of the vigilance contact person.

Affected workflows

Inspection Readiness

Responsible groups

Quality AssuranceComplianceMedical Device Safety

PV impact

Updates the inspection framework for medical device vigilance in Switzerland; hospitals and potentially associated MAH stakeholders should use the checklist to ensure incident reporting compliance.

View regulator source

Source document details

Exact policy details

Applicable Legislation
The health facility identifies and applies relevant laws and regulations for its operations.
Applies to: All healthcare facilities conducting medical device vigilance
1.3.1 · p. 1 · High · Source
Quality Management Responsibility
The management is responsible for implementing regulatory requirements regarding vigilance processes.
Applies to: Healthcare facility management
3.1, 3.3 · p. 1 · High · Source
Retention Period for Records
Documents related to materiovigilance must be retained for at least 15 years.
Applies to: All medical device documentation
3.7, 6.1, 6.10, 8.5 · p. 1 · High · Source
Notification of Serious Incidents
Serious incidents must be reported within 2, 10, or 15 days depending on the severity.
Applies to: Healthcare facilities reporting serious incidents
6.1, 6.6 · p. 1 · High · Source
Vigilance Contact Person
A vigilance contact person must be appointed and reported to Swissmedic.
Applies to: Every healthcare facility
3.3.2 · p. 1 · High · Source

Evidence and confidence

Confidence: highSource updated: Jul 17, 2026

Full briefing

Practical implication

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Swissmedic has published a checklist to assist healthcare facilities in Switzerland with evaluating their compliance with medical device vigilance (materiovigilance) requirements. This checklist is designed to help identify gaps in adherence to the GPMV-Spital standards and is crucial for ensuring proper incident reporting mechanisms are in place.

What changed: The introduction of a formal checklist tool for hospital inspections regarding materiovigilance, enhancing standards for incident reporting and vigilance roles.

Why it matters: The checklist establishes a framework for hospitals and associated stakeholders to ensure vigilance compliance, thus improving patient safety and regulatory adherence in the handling of medical devices.

Practical implication: Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFood and Drug Administration (FDA) · United States · Updated Jun 29, 2026

eMDR System Enhancements - Production Deployment

Urgency: High

Update electronic safety reporting systems and pharmacovigilance databases to implement new rules to ensure all submissions use GENC 3-letter country codes and include the required fields as of July 20, 2026.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward